Skip to main content
Insmed Incorporated (BST:IM8N)
Germany flag Germany · Delayed Price · Currency is EUR
115.72
+0.66 (0.57%)
At close: Apr 27, 2026

Insmed Statistics

Total Valuation

Insmed has a market cap or net worth of EUR 25.02 billion. The enterprise value is 24.44 billion.

Market Cap 25.02B
Enterprise Value 24.44B

Important Dates

The next confirmed earnings date is Thursday, May 7, 2026.

Earnings Date May 7, 2026
Ex-Dividend Date n/a

Share Statistics

Current Share Class 215.85M
Shares Outstanding n/a
Shares Change (YoY) +21.32%
Shares Change (QoQ) +0.89%
Owned by Insiders (%) 0.62%
Owned by Institutions (%) 90.66%
Float 193.49M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 48.44
PB Ratio 39.75
P/TBV Ratio 55.61
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a

Enterprise Valuation

EV / Earnings -22.47
EV / Sales 47.28
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF -29.66

Financial Position

The company has a current ratio of 3.83, with a Debt / Equity ratio of 1.01.

Current Ratio 3.83
Quick Ratio 3.35
Debt / Equity 1.01
Debt / EBITDA n/a
Debt / FCF -0.77
Interest Coverage -11.87

Financial Efficiency

Return on equity (ROE) is -249.28% and return on invested capital (ROIC) is -40.32%.

Return on Equity (ROE) -249.28%
Return on Assets (ROA) -28.99%
Return on Invested Capital (ROIC) -40.32%
Return on Capital Employed (ROCE) -55.40%
Weighted Average Cost of Capital (WACC) n/a
Revenue Per Employee 310,391
Profits Per Employee -653,503
Employee Count 1,664
Asset Turnover 0.28
Inventory Turnover 1.07

Taxes

In the past 12 months, Insmed has paid 4.28 million in taxes.

Income Tax 4.28M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +89.71% in the last 52 weeks.

Beta (5Y) n/a
52-Week Price Change +89.71%
50-Day Moving Average 126.76
200-Day Moving Average 112.31
Relative Strength Index (RSI) 37.10
Average Volume (20 Days) 202

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) 6.02

Income Statement

In the last 12 months, Insmed had revenue of EUR 516.49 million and -1.09 billion in losses. Loss per share was -5.47.

Revenue 516.49M
Gross Profit 411.78M
Operating Income -847.25M
Pretax Income -1.08B
Net Income -1.09B
EBITDA -835.06M
EBIT -847.25M
Loss Per Share -5.47

Balance Sheet

The company has 1.22 billion in cash and 638.38 million in debt, giving a net cash position of 579.59 million.

Cash & Cash Equivalents 1.22B
Total Debt 638.38M
Net Cash 579.59M
Net Cash Per Share n/a
Equity (Book Value) 629.39M
Book Value Per Share 2.94
Working Capital 1.13B

Cash Flow

In the last 12 months, operating cash flow was -796.35 million and capital expenditures -27.73 million, giving a free cash flow of -824.08 million.

Operating Cash Flow -796.35M
Capital Expenditures -27.73M
Depreciation & Amortization 12.22M
Net Borrowing -4.21M
Free Cash Flow -824.08M
FCF Per Share n/a

Margins

Gross margin is 79.73%, with operating and profit margins of -164.04% and -210.54%.

Gross Margin 79.73%
Operating Margin -164.04%
Pretax Margin -209.71%
Profit Margin -210.54%
EBITDA Margin -161.68%
EBIT Margin -164.04%
FCF Margin n/a

Dividends & Yields

Insmed does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -21.32%
Shareholder Yield -21.32%
Earnings Yield -4.35%
FCF Yield -3.29%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Insmed has an Altman Z-Score of 5.13 and a Piotroski F-Score of 4.

Altman Z-Score 5.13
Piotroski F-Score 4